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Abstract
Clostridium difficile infections (CDIs) are traditionally seen in elderly and hospitalized patients who have used antibiotic therapy. In the
community, CDIs requiring a visit to a general practitioner are increasingly occurring among young and relatively healthy individuals
without known predisposing factors. C. difficile is also found as a commensal or pathogen in the intestinal tracts of most mammals, and
various birds and reptiles. In the environment, including soil and water, C. difficile may be ubiquitous; however, this is based on limited
evidence. Food products such as (processed) meat, fish and vegetables can also contain C. difficile, but studies conducted in Europe
report lower prevalence rates than in North America. Absolute counts of toxigenic C. difficile in the environment and food are low,
however the exact infectious dose is unknown. To date, direct transmission of C. difficile from animals, food or the environment to
humans has not been proven, although similar PCR ribotypes are found. We therefore believe that the overall epidemiology of human
CDI is not driven by amplification in animals or other sources. As no outbreaks of CDI have been reported among humans in the com-
munity, host factors that increase vulnerability to CDI might be of more importance than increased exposure to C. difficile. Conversely,
emerging C. difficile ribotype 078 is found in high numbers in piglets, calves, and their immediate environment. Although there is no
direct evidence proving transmission to humans, circumstantial evidence points towards a zoonotic potential of this type. In future
emerging PCR ribotypes, zoonotic potential needs to be considered.
Keywords: Animal, Clostridium difficile, Clostridium difficile infections, community-acquired, zoonosis
Article published online: 24 March 2012
Clin Microbiol Infect 2012; 18: 635–645
Corresponding author: E. J. Kuijper, Department of Medical
Microbiology, Leiden University Medical Centre, PO Box 9600, 2300
RC Leiden, The Netherlands
E-mail: e.j.kuijper@lumc.nl
Introduction
Clostridium difficile is an anaerobic, spore-forming bacterium
that can produce toxin A or B upon colonization of the gut.
Patients at risk for C. difficile infection (CDI) subsequently
develop diarrhoea or, in severe cases, a pseudomembranous
colitis. Traditionally, elderly and hospitalized patients who
had used antibiotic therapy were considered to be the most
vulnerable to CDI [3]. Because these high-risk patients are
primarily located in healthcare facilities, CDI was regarded as
a primarily nosocomial disease for many years. This concept
is now being challenged, because persons outside hospitals
are increasingly developing CDI [4–7].
When CDI is acquired in a healthcare facility, symptoms
may start during hospitalization, but they may also develop
after discharge. Subsequently, 25–50% of the patients who
develop CDI outside a hospital have had a recent hospital
admission [5,8,9]. For this review, we define community-
acquired CDI (CA-CDI) as follows: patients with symptoms
of CDI starting in the community or within 48 h of admis-
sion to a healthcare facility, provided that the onset was
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more than 12 weeks after the last discharge from a health-
care facility, according to guidelines from the European Cen-
tre for Disease Prevention and Control and the CDC [1,2].
Some studies include in this review have modified this
definition (Table 1). A clear definition of CDI is necessary to
distinguish between healthcare-acquired CDI and CA-CDI.
Besides its presence in humans, C. difficile has also been
described as a commensal or pathogen in numerous animal
species. Because patients with CA-CDI do not, by defini-
tion, acquire C. difficile in a hospital, the question arises as
to what the source of exposure might be in the commu-
nity. Direct or indirect contact with animals was proposed
as a possible source of C. difficile. This review describes the
occurrence of CA-CDI and discusses the potential sources
of C. difficile in the community. Furthermore, it summarizes
the evidence for C. difficile being considered as a new zoo-
notic agent.
Occurrence of CDI in the Community
CDI is frequently diagnosed within healthcare facilities, and
the incidence can rise above 200 per 10 000 admissions [10].
The incidence of CDI occurring outside healthcare facilities
is significantly lower [11]. Nevertheless, CDI acquired in the
community accounts for one-quarter of all diagnosed CDI
patients [7,11,12]. Table 1 summarizes studies investigating
the incidence of CA-CDI, and shows the study population,
the definition of CA-CDI applied, the test that was used, and
the incentive to test patients for CDI. In four studies,
an enzyme immunoassay was used to diagnose CDI. Enzyme
immunoassays have been criticized recently for their low
sensitivity, despite their good specificity [9,12–14]. However,
even a relatively specific test will give false-positive results in
a low-incidence setting such as the community [15], and this
will impact on a reliable estimation of the incidence. The
incentive to test for CDI also affects the incidence. When
patients are tested only upon request of the physician,
patients without known risk factors for CDI may be missed.
Half of the studies reported in Table 1 [5,7,11–13,16–20]
only tested faeces samples for C. difficile on request of the
physician. Despite the relatively similar incidence rates that
are reported, most studies are likely to under-report the
real occurrence of CDI, owing to their methodological
weaknesses.
The population-based study by Wheeler et al. [21] was
the only study that tested all diarrhoeal patients in the com-
munity, regardless of whether patients visited a general prac-
titioner (GP) or whether CDI was suspected. Between 1993
and 1997, they included 9776 patients, randomly selected
from the GPs’ patient lists, and prospectively questioned
them about the occurrence of diarrhoea during six consecu-
tive months. Diarrhoea occurred in 781 cases, and six of
these patients were found to be positive for C. difficile by the
use of Vero cells, resulting in an incidence of 160 per
100 000 persons per year. Microbiological studies in the
community are scarce, and all other studies in Table 1 were
performed among patients with diarrhoea visiting their GP.
These studies report an incidence of CDI of 7–25 per
100 000 persons per year [5,11–13,16,18,19,21,21,22], which
is eight-fold lower than the incidence found in the commu-
nity. This difference suggests that many patients do not seek
medical attention for mild diarrhoea caused by C. difficile
[21]. When the number of people serviced by a laboratory
or hospital (catchment area) is unknown, incidences cannot
be determined, and only the percentage of positive tests can
be reported. Patients presenting to the GP with diarrhoea
have a positive test result for CDI in 2–6% of cases
[9,17,23–26]. This increases to c. 10% when antibiotics are
used or a physician specifically requests testing, often
because risk factors are present [23,27].
Campylobacter, Salmonella, Yersinia and Shigella are more
frequent causes of diarrhoea diagnosed by GPs, according to
Wheeler et al. [21]. An Australian study detected C. difficile
in 89 patients, and 36 of the isolates produced toxins (2.1%
of the total). Toxigenic C. difficile was also less frequent than
Campylobacter (3.2%), Shigella (3.2%) and Salmonella (2.9%) in
this study [24]. Both studies were performed before the inci-
dence of CDI increased worldwide in the beginning of the
20th century. In 2007, a small Austrian study concluded that
CDI was the most frequent bacterial cause of gastroenteritis
in general practice [28]. However, this finding should be
interpreted with caution, as the incidence of CDI was
extraordinarily high (236/100 000), possibly because of the
use of a test with a low positive predictive value [29] (Immu-
noCard; Meridian Bioscience, Cincinnati, OH, USA) and the
inclusion of patients with a history of recent hospital admis-
sion [28].
Studies on patients with severe community-acquired diar-
rhoea requiring hospital admission who were subsequently
diagnosed with CDI are not given in Table 1. It is estimated
that these patients account for over 5% of all hospitalized
CDI patients, emphasizing the importance of better guide-
lines for the diagnosis of CA-CDI [13,30]. Kuntz et al. [18]
and Riley et al. [23] reported that 6% of CA-CDI patients
are treated for a recurrence. Bauer et al. [9] found a higher
recurrence rate (29%); however, this study also included
patients with a recent hospital admission. Although about
10% of the CA-CDI patients who are diagnosed by their GPs
are hospitalized during the course of their disease [16,22],
CMI Hensgens et al. CA-CDI: a zoonotic disease? 637
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CDI-related mortality rates in this group of patients are very
low (£3%) [22,30,31].
Patient and Strain Characteristics in
CA-CDI
Patients with CA-CDI do not have the classic risk profile of
patients who develop CDI in a healthcare facility. Only 32–
88% used antibiotic therapy before their diarrhoea, and the
mean age was below 65 years in all but one study (Table 1)
[5]. Four studies that reported relatively low antibiotic usage
might have suffered from patient recall bias [14,26,28,31].
However, a large study performed by Dial et al. that used a
drug prescription database also concluded that only 36% of
patients with CA-CDI used an antibiotic. Therefore, the vari-
ations in reported antibiotic use are probably attributable to
the varying time intervals in which the data were gathered
and the differences in study populations. In a statewide sur-
veillance study in Connecticut, 241 cases with confirmed
CA-CDI were reported by healthcare providers to the
Department of Public Health. One-quarter of them had no
underlying illness or hospitalization in the preceding year
[19]. Similar results were seen in four other studies, where
16%, 26%, 35% and 40% had no antibiotic use or admission
preceding their CA-CDI [22,26,31,32]. Furthermore, severe
CDI was reported among previously low-risk populations,
such as healthy individuals and pregnant women [4]. The
emergence of CDI among pregnant women was only
reported in two small studies of ten patients [4,33], the
majority of whom had a history of prior antibiotic therapy.
Larger studies have not confirmed the emergence of CDI in
pregnancy. The susceptibility to CDI of patients without tra-
ditional risk factors is not well understood. Proton-pump
inhibitors, which are used to treat reflux disease and peptic
ulcers, were postulated to increase vulnerability to C. difficile.
Several studies reported discrepant results, and there is no
consensus on whether this frequently used treatment predis-
poses to CDI [5,30,34,35]. Identification of additional factors
that increase vulnerability is therefore needed. The selection
of an appropriate control group is essential for this purpose.
Many recent studies compared hospitalized CDI patients
with CDI patients from the community, which will not result
in the identification of new risk factors.
In order to explain the emergence of CA-CDI, new
routes of transmission have been considered. A disease
transmission model proposed by Otten et al. [36] mentioned
four potential sources: the environment, contact with
infected or colonized patients, contact with infected or colo-
nized animals, and foodborne transmission. Increased expo-
sure to one or more of these sources might explain the
increase in the number of cases of diagnosed CA-CDI. How-
ever, as no outbreaks of CDI have been reported in the
community, host factors that increase vulnerability might be
of more importance in the development of CDI than
increased exposure to C. difficile.
A study of 57 patients with CA-CDI who were diagnosed
by their GPs showed an association between CDI and con-
tact with infants under 2 years of age in univariate analysis
[22]. This association had not been found previously, possibly
because it had not been looked for. The absence of a multi-
variate analysis implies that this association could have
resulted from confounding. However, infants are known to
be frequently colonized (c. 40%) with toxigenic C. difficile
[37]. These children rarely develop symptoms, and this is
hypothesized to be attributable to the lack of a receptor for
toxin A, but evidence for this hypothesis is lacking.
Information on the strains of C. difficile isolated from
patients with CA-CDI is scarce and is available from only a
few small studies. The most frequently found PCR ribotypes
were 078, 001, and 014 [9,38,39]. These ribotypes are also
among the most prevalent in hospitals [40,41]. Ribotype 027,
however, was also found in smaller numbers than in hospitals
[38,42]. Strains such as ribotype 027, especially its spores,
spread more easily within the hospital, because they can
resist the hospital environment, cleaning, and disinfectants
[43]. Variation in antibiotic prescriptions might account for
the higher prevalence of ribotype 027 in hospitals.
C. difficile in Animals and Potential for
Transmission
CDI in animals was unknowingly described in 1968, when
Small [44] reported a case of fatal enteritis in laboratory ham-
sters after administration of antibiotics. Since then, hamsters
have been used as animal models to prove the association of
C. difficile with pseudomembranous colitis in humans [45].
C. difficile has been isolated from almost all mammals [46,47],
including cows, horses [48], pigs [49], elephants [50], Kodiak
bears [51], and non-human primates [52], and also in poultry
[53] and ostriches [54]. In contrast to human medical
research, where studies are mostly focused on the role of
C. difficile in disease, many studies in animals concentrate on
the presence of the bacterium in healthy animals. Investiga-
tions on the role of household pets as a possible reservoir of
C. difficile showed that both healthy and diseased dogs and
cats can shed spores of C. difficile [55,56]. Riley et al. [56]
sampled dogs and cats that were treated for a variety of rea-
sons at two veterinary clinics, using selective solid and enrich-
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ment media, and found C. difficile in 39.5%. At both clinics,
the environment also became grossly contaminated with
C. difficile, as 40% and 75% of the sites were positive. Both
toxigenic and non-toxigenic C. difficile isolates were recov-
ered, but no overlap between animal and human isolates of
C. difficile was found after typing [57]. In 2010, C. difficile colo-
nization of pets and contamination of households was again
evaluated by Weese et al. [58]. In 26 (31%) of the 84 house-
holds that were sampled, 14 (10%) of 139 dogs and three
(21%) of 14 cats were positive for C. difficile. Again, no over-
lap between canine isolates and environmental isolates was
seen after PCR ribotyping. In contrast to other studies,
where the predominant PCR ribotype in dogs and cats was
the non-toxigenic 010, the most common PCR ribotype in
dogs and cats in this study was 001 [59,60]. This was also the
most common PCR ribotype among humans in the study area
[58]. In fact, all toxigenic isolates from the pets in this study
are known to be implicated in human CDI.
PCR ribotypes known to be involved in human CDI were
also isolated from horses [59,61]. Keel et al. [59] and Koene
et al. [60] reported a diversity of PCR ribotypes (>10 differ-
ent types) in horses. Ribotype 015 was predominant accord-
ing to Keel et al., whereas the Dutch study did not find a
predominant PCR ribotype. Songer et al. [62] reported a case
of fatal typhlocolitis caused by ribotype 027 in a 14-year-old
quarter horse. C. difficile seems to be a rare finding in healthy
adult horses, as a low prevalence (0–1.2%) is reported for
horses without signs of diarrhoea [63,64]. The prevalence of
the bacterium is higher in adult horses with diarrhoea and in
foals, where it varies from 6% to 40% [63,64].
Most of the published research on C. difficile in animals has
been focused on production animals. The first large-scale
study in food-producing animals was conducted in 1996 by al
Saif and Brazier [49], and although at least 100 animals from
every animal species in the study, i.e. cattle, sheep, poultry,
pigs, and horses, from 40 different farms were sampled,
C. difficile was isolated only rarely. The highest prevalence
was found in poultry (1.6%), and the bacterium was not iso-
lated from the pigs or cattle [49]. The age of the sampled
animals was unknown, and because older age in animals is
associated with a low C. difficile prevalence [65], the results
of this study could be attributable to an age effect. Since the
beginning of the 21st century the epidemiology of C. difficile
in production animals has changed, because C. difficile is
increasingly being reported as a major cause of neonatal
enteritis in piglets [66–68]. Even though the postulate of
Koch was confirmed in two different studies in which piglets
inoculated with C. difficile spores developed characteristic
gross and microscopic signs of disease [67,69], the role of
the bacterium in disease in pigs is still questioned, as no
association between diarrhoea and presence of the bacte-
rium was found in a large Spanish study [70]. No clear cor-
relation between disease and the presence of the bacterium
was found in calves either [71,72]. The PCR ribotypes of iso-
lates originating from cattle and pigsare much less diverse
than those from dogs, horses, and humans [59]. The pre-
dominant PCR ribotype is 078, which accounted for 94% and
83% of the bovine and swine isolates in the study by Keel
et al. [59] and for 100% of the isolates in a study by Keessen
et al. [73]. In poultry, the association between enteritis and
colonization with C. difficile is less well studied [53,74,75].
Zidaric et al. ribotyped 44 isolates from two separate flocks
at one poultry farm. A wide variety of 12 different PCR ribo-
types was found, with none of them being predominant [53].
An overview of the predominant PCR ribotypes of C. difficile
in animal species is given in Table 2.
Although the issue of zoonotic transmission of C. difficile
was raised more than 20 years ago, and the finding of over-
lapping PCR ribotypes in animals and humans has stimulated
research in this field, the question of whether zoonotic
transmission occurs has not been answered. Circumstantial
evidence that C. difficile strains from animals were infecting
humans (or vice versa) has been reported several times in
recent years [59,76]. These studies have taken animal and
human isolates and typed them by molecular methods, and
TABLE 2. Clostridium difficile in animal species
Animal
species
Predominant
ribotype
Frequency,
N type/
total (%)
Study
period References
Dogs 010 5/12 (42) 2007 (published) Keel et al. [5959]
010 12/29 (41) 2009–2010 Koene et al. [60]
001 4/14 (29) 2005–2006 Weese et al. [58]
014 7/29 (24) 2009–2010 Koene et al. [60]
Cats 010 9/18 (50) 2009–2010 Koene et al. [60]
039 5/18 (28) 2009–2010 Koene et al. [60]
Horses 015 6/20 (30) 2007 (published) Keel et al. [5959]
Pigs 078 33/33 (100) 2008 (published) Debast et al. [7979]
078 66/66 (100) 2009 Keessen et al. [73]
078 93/144 (84) 2007 (published) Keel et al. [5959]
078 7/9 (78) 2009–2010 Koene et al. [60]
066 166/247 (67) 2009 (published) Avbersek et al. [61]
066 66/133 (50) 2008 (published) Pirs et al. [110]
SL011a 74/247 (30) 2009 (published) Avbersek et al. [61]
SL011a 31/133 (23) 2008 (published) Pirs et al. [110]
126 16/144 (11) 2007 (published) Keel et al. [5959]
002 6/144 (4) 2007 (published) Keel et al. [5959]
029 7/247 (3) 2009 (published) Avbersek et al. [61]
Cattle 078 31/33 (94) 2007 (published) Keel et al. [5959]
078 31/33 (94) 2008 (published) Hammitt et al. [111]
012 5/6 (83) 2009–2010 Koene et al. [60]
017 8/31 (26) 2004 Rodriguez-Palacios
et al. [71]
078 7/31 (23) 2004 Rodriguez-Palacios
et al. [71]
027 4/31 (13) 2004 Rodriguez-Palacios
et al. [71]
014 4/31 (13) 2004 Rodriguez-Palacios
et al. [71]
aThis type could not be identified.
Only when a ribotype was encountered in at least four animals per animal spe-
cies are results included.
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have shown overlap between isolates in the two groups. For
example, Arroyo et al. [76] looked at 133 isolates of C. difficile
from dogs (n = 92), horses (n = 21), and humans (n = 20),
plus one each from a cat and a calf. Overall, 23 different PCR
ribotypes were identified. Of these, nine were identified from
dogs, 12 from horses, seven from humans, and one each from
the cat and calf. Although absolute numbers were small, 25%
of the human isolates were indistinguishable from animal iso-
lates according to PCR ribotyping. Keel et al. [59] examined a
similar number of isolates (n = 144), and again showed simi-
larities between horse, dog and human isolates of C. difficile
with PCR ribotyping, but not with isolates from cattle or pigs.
Other, more discriminatory, typing methods for C. difficile,
such as multilocus variable-number tandem-repeat analysis or
microarrays, also showed overlap between human and animal
isolates [77–79]. Whether C. difficile strains in humans and
animals are really identical should be determined by, for
example, whole genome sequencing. The similarities seen in
strains of human patients and different animal species do not
automatically imply that interspecies transmission occurs.
However, as living with an immunocompromised person is a
risk factor for colonization with C. difficile for dogs, However,
as living with an immunocompromised person is a risk factor
for colonization with C. difficile for dogs [58], and the risk of
C. difficile colonization of hospital visitation dogs is associated
with close human contact [80], interspecies transmission is
likely to occur.
In The Netherlands, an overlap between the location of
pig farms and the occurrence of human C. difficile ribo-
type 078 infections, which are increasing in prevalence, is
observed [81]. The fact that infections with ribotype 078 in
humans occurred in a younger population and were more
frequently community-acquired than infections with ribo-
type 027 strains, together with the fact that 078 is the
predominant PCR ribotype in piglets, suggested a common
source [81]. This common source is likely to be the environ-
ment. If infection rates in pig farms in The Netherlands are
as high as those in the USA [66], it is likely that a large
proportion of the Dutch population comes into contact with
C. difficile spores every day, especially as The Netherlands
has one of the highest population densities in the world.
There is little evidence that other epidemic strains have
zoonotic potential.
Environmental Contamination
Because of its spore-forming ability, C. difficile can survive in
the environment for several months. The presence of C. diffi-
cile spores in hospitals is well established [82]. Also, gross
contamination of farms such as pig facilities with C. difficile
spores is commonplace. C. difficile could be isolated from the
faeces of piglets 1 h after birth, presumably ingested from
their environment. Within 2 days of birth, 100% of piglets
had acquired C. difficile of the same molecular type that was
found in sow faeces, sow teats, farrowing crates, and air on
the farm [83]. There is evidence that vertical transmission
does not occur in pigs [83]. Aerial dissemination of C. difficile
on a pig farm has been shown to correlate with the activity
of personnel within farrowing units [84], suggesting that staff
might be at increased risk of ingesting airborne C. difficile
spores. Contamination of the pig farm environment was con-
firmed in another study where C. difficile prevalence in the
environment increased from 0% to 61% of sites within a pig
farrowing facility only 1 month after it had been occupied by
pigs [85]. C. difficile spores and vegetative cells are shed into
the immediate environment in the faeces of both scouring
and non-scouring pigs, underscoring the importance of high
carriage rates in apparently healthy piglets [83]. The carrier
state has also been emphasized in mouse studies that have
demonstrated a marked increase in spore shedding when
antibiotics are given to asymptomatic carrier mice. Subse-
quent spore-mediated transmission to immunosuppressed
mice led to severe intestinal disease [86]. Another important
consideration in relation to environmental contamination is
effluent arising from piggeries. In Australia, piggery effluent is
treated in anaerobic ponds to remove pathogens, and
re-used to wash sheds or applied to agricultural land. C. difficile
was shown to survive this process, with concentrations of via-
ble C. difficile spores of >200 CFU/mL (MM, Squire and TV,
Riley, unpublished data) posing a risk for infection of animals or
contamination of agricultural produce.
Besides environmental contamination in the vicinity of col-
onized or infected humans and animals, C. difficile spores can
be isolated from practically any environmental site, provided
that the correct culture enrichment methods are employed
[87]. A large study by al Saif and Brazier [49] showed high
rates of detection of C. difficile in soil and water samples in
South Wales. Soil contained C. difficile in 21% of 104 samples,
and 41% of the isolates produced toxin A. Water was posi-
tive in 88% of river samples, half of the sea, lake and swim-
ming pool samples, and 5.5% of the tap water samples.
Overall, 85% of the isolates produced toxin A. In 2010, simi-
lar percentages were found in Slovenia [88], where 61% (42
of 69) of the river isolates were positive for C. difficile. Inter-
estingly, 34 different types were found, more than half of
which were also found in humans and animals. Ribotype 014,
a common PCR ribotype found in humans, was the most
prevalent (16%). Although absolute counts of toxigenic
C. difficile in water are low (1–5 CFU/100 mL) [49], the
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infectious dose is unknown, and therefore so is the impact
of the environment as a source of human or animal CDI.
C. difficile in Food Products
As C. difficile can be detected in live animals, foodborne
transmission via meat is also considered to be a potential
source of CA-CDI. Recently, a number of studies have been
published on the prevalence of C. difficile in (processed)
meat, fish, and vegetables. These results are summarized in
Table 3.
Remarkably, studies conducted in Europe have persistently
reported low prevalence rates, e.g. in up to 3% of meat sam-
ples [89–94], in contrast to the USA and Canada, where
C. difficile is generally reported at much higher rates, e.g. in
up to 42% of meat samples [95–103]. Although high isolation
frequencies are reported for C. difficile in meat, quantitative
TABLE 3. Clostridium difficile in food products
Country
Sample
material
N positive
samples/N
tested
samples (%)
N toxinogenic/N
all isolates (%)
RT 078 or
related
strainsa (%)
RT 027 or
related
strainsb (%)
Other
toxinogenic
types (%) References
Retail beef and veal
North America Canada Ground meat 12/60 (20.0) 11/12 (91.2) – 8/12 (66.7) RT 077 (16.7)
RT 014 (8.3)
Rodriguez-Palacios
et al. [95]
Canada Ground beef and
veal chops
13/214 (6.1) 12/15 (80.0) – 4/15 (26.7) RT 077 (20.0)
RT 014 (13.3)
NAP9 (6.7), C
(6.7), H (6.7)
Rodriguez-Palacios
et al. [96]
USA Cooked/uncooked
beef
14/33 (42.4) 14/14 (100) 10/14 (71.4) 4/14 (28.6) – Songer et al. [97]
Canada Ground beef 14/115 (12.2) 14/14 (100) 12/14 (85.7) 1/14 (7.1) Toxinotype IX (7.1) Weese et al. [98]
USA Ground veal 4/50 (8.0) 3/4 (75.0) NT NT NT Houser et al. [103]
Europe Sweden Ground beef 2/82 (2.4) 2/2 (100) NT NT NT Von Abercron
et al. [90]
France Ground beef 2/105 (1.9) 2/2 (100) – – RT 012 (100) Bouttier et al. [91]
Austria Ground beef 0/30 (0) – – – – Jobstl et al. [93]
Ground beef/pork 3/70 (4.3) 1/3 (33.3) – – RT 053 (33.3)
The
Netherlands
Beef/calf 0/164 (0) – – – – De Boer et al. [94]
Switzerland Ground beef/pork 0/46 (0) – – – – Hoffer et al. [92]
Retail pork
North America USA Cooked/uncooked
pork
19/46 (41.3) 19/19 (100) 13/19 (68.4) 6/19 (31.6) – Songer et al. [97]
Canada Ground pork 14/115 (12.2) 14/14 (100) 10/14 (71.4) 1/14 (7.1) Toxinotype IX (7.1)
Toxinotype 0 (7.1)
Toxinotype III (7.1)
Weese et al. [98]
Canada Ground pork and
pork chops
7/393 (1.8) 6/7 (85.7) – 4/7 (57.1) Toxinotype 0 (14.3)
Toxinotype XXVI (14.3)
Metcalf et al. [9999]
USA Pork and swabs 23/243 (9.5) 23/23 (100) 22/23 (95.6) – Toxinotype XI (4.3) Harvey et al. [101]
Europe Austria Pork 0/27 (0) – – – – Indra et al. [8989]
Austria Ground beef/pork 3/70 (4.3) 1/3 (33.3) – – RT 053 (33.3) Jobstl et al. [93]
France Pork sausage 0/59 (0) – – – – Bouttier et al. [91]
Switzerland Ground beef/pork 0/46 (0) – – – – Hoffer et al. [92]
The
Netherlands
Pork 0/63 (0) – – – – De Boer et al. [94]
Poultry products
North America USA Turkey 4/9 (44.4) 4/4 (100) 4/4 (100) – – Songer et al. [97]
Canada Chicken meat 26/203 (12.8) 26/26 (100) 26/26 (100) – – Weese et al. [100]
USA Chicken meat 4/32 (12.5) 7/7 (100) 7/7 (100) – – Harvey et al. [101]
Europe Austria Chicken meat 0/6 (0) – – – – Indra et al. [8989]
The
Netherlands
Chicken meat 7/257 (2.7) 4/7 (57.1) – – RT 001 (14.3)
RT 003 (28.6)
RT 087 (14.3)
De Boer et al. [94]
Other food and feed products
North America Canada Vegetables, divers 5/111 (4.5) 5/5 (100) 3/5 (60.0) – NAP4/toxinotype
0 (40.0)
Metcalf et al. [9999]
Canada Seafood/fish 5/119 (4.2) 4/5 (80.0) 4/5 (80.0) – – Metcalf et al. [105]
Canada Dog and cat feed 1/25 (4.0) NT NT NT NT Weese et al. [112]
Europe UK Raw vegetables
Fish gut contents
7/300 (2.3)
0/107 (0)
5/7 (71.4) NT NT NT al Saif and Brazier
[4949]
UK Ready-to-eat salads 3/40 (7.5) 3/3 (100) – – RT 017 (66.7),
RT 001 (33.3)
Bakri et al. [107]
Austria Raw milk 0/50 – – – – Jobstl et al. [93]
NT, not tested; RT, ribotype.
aNAP07, toxinotype V or related strains.
bNAP01, toxinotype III, M31 or related strains.
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studies show that levels of contamination are generally low,
with <100 CFU/g in chicken meat [100] and typically 20–
240 spores/g in retail beef and pork [98]. Despite the low
numbers, the spore-forming nature of C. difficile and the heat
tolerance of the spores [95] might facilitate foodborne trans-
mission [100]. The majority of C. difficile isolates that have
been recovered from food are toxigenic and therefore
potentially pathogenic, with a clear overlap in types being
found in human patients. Ribotypes 078 and 027 have not
been isolated from meat samples in Europe, but are the main
PCR ribotypes found in food in North America (Table 3).
However, this finding needs to be confirmed, because labo-
ratory cross-contamination may have occurred in some stud-
ies [104]. If we exclude the study by Songer et al. [97], who
found a high prevalence rate, the overall prevalence of C. dif-
ficile in meat samples in North America drops to 2–20%, and
more resembles the percentages found in Europe. Meat has
been given most attention, and limited information is avail-
able for other food products. C. difficile has been found in
seafood and fish [49,105], and also in vegetables [49,106,107]
and environmental samples [49]. So far, the isolation of C. dif-
ficile from milk and milk products has not been reported,
despite the presence of C. difficile in cattle faeces.
Whether the differences observed between countries, both
in overall prevalence rates and in PCR ribotypes, truly reflect
geographical differences in occurrence, reflect temporal or
seasonal differences in prevalent PCR ribotypes or perhaps
are caused by other factors is presently unknown, and needs
further investigation. Conceivably, the differences are affected
by the use of different methodologies, although these do not
seem to be related to distinct regions. Poor reproducibility
with some methodologies has been shown, suggesting that
present culture methods might be suboptimal for the detec-
tion of C. difficile in meat samples [96,108]. Furthermore, the
interpretation of findings is hampered by the use of different
sampling methods. Validated methodologies for the sampling
and isolation of C. difficile from food and environmental sam-
ples are urgently needed. The source of contamination with
C. difficile in retail meats is also presently unknown. It may
involve faecal or environmental contamination of carcases, or
contamination during processing by shedding handlers [95,97].
In addition, ante-mortem deposition of (dormant) spores in
the animal’s muscle or other tissues has been suggested as a
possible food contamination route [96,108].
Although C. difficile is present in food for human consump-
tion, and overlapping PCR ribotypes from animal and human
sources have been reported [57,76,109], foodborne infection
caused by C. difficile has never been confirmed. Further stud-
ies are required to provide relevant data on the sources,
transmission routes, growth and survival of C. difficile in
foods. Additionally, more information on the infective dose
and more quantitative information on the level of contamina-
tion are needed to further measure the risks for humans
associated with foodborne exposure to C. difficile.
Conclusion
C. difficile frequently causes mild, self-limiting diarrhoea in the
community. Only a minority of the patients seek medical
attention. C. difficile is also found in animals, food products
and the environment. To date, direct transmission from one
of these sources to humans has not been proven, and there
is little evidence that frequently found PCR ribotypes such as
001, 014 and 027 have a zoonotic source. We therefore
believe that the overall epidemiology of human CDI is not
driven by amplification in animals. However, because almost
all PCR ribotypes are able to colonize or infect different
hosts, and host-specific PCR ribotypes do not seem to
occur, we assume that zoonotic transmission is possible. The
emergence of C. difficile ribotype 078 in humans is epidemio-
logically linked to its presence in piglets, calves, and their
environment, suggesting zoonotic transmission. Because this
evidence is circumstantial, it needs to be determined
whether patients at risk for CDI can truly be infected by
these animals or their environment. The risk for infection of
persons in close contact with these animals is likely to be
small, although preliminary data indicate that colonization
frequently occurs (E. C. Keessen, manuscript in preparation).
The zoonotic potential of other frequently found pathogenic
C. difficile PCR ribotypes is probably very low. However,
when new PCR ribotypes emerge, zoonotic transmission
should always be considered.
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